Asahi Kasei Acquired US pharmaceutical company for 140 billion yen Established pharmaceutical business base November 25, 18:33
Asahi Kasei, a major chemical manufacturer, announced that it will acquire an American pharmaceutical company for approximately 140 billion yen in order to strengthen its pharmaceutical business, which is expected to grow.
This is what Asahi Kasei announced at a press conference in Tokyo on the 25th, investing approximately 14.32 billion yen to acquire "Veroxis" a pharmaceutical company based in North Carolina in the southern United States.
According to Asahi Kasei, “Beloxis” has strengths in products such as immunosuppressants used in kidney transplant surgery, and this acquisition aims to lay the foundation for the pharmaceutical business in the United States.
Asahi Kasei says that it will acquire all shares of the parent company of “Beloxis” in Denmark through a tender offer, and the management of “Beloxis” agrees with the acquisition by Asahi Kasei.
Asahi Kasei's mainstay automotive materials business is sluggish due to the slowdown in the Chinese economy against the backdrop of trade friction between the United States and China, but the healthcare business, including pharmaceuticals, has been strong. We were considering further strengthening.
Asahi Kasei President Hideaki Kobori said at the conference, “In an uncertain era, having three business areas—materials, housing, and healthcare—is important for stable growth. I want to expand my business from a big US to the world. "